Paper Details

  1. Home
  2. Paper Details

Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.

Author: AhnSang Hoon, ButiMaria, CaruntuFlorin A, ChanAlain, ChanHenry L Y, ChuangWan-Long, CransGerald, ElkhashabMagdy, FlisiakRobert, FungScott, GaetaGiovanni B, GuyerWilliam, HuiAric J, JumpBelinda, MaXiaoli, MarcellinPatrick, MehtaRajiv, PapatheodoridisGeorge, PetersenJörg, SubramanianMani, TabakFehmi, TakWon Young

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study evaluating the achievement of HBsAg loss with a finite course of oral antiviral therapy found that significantly higher rates of HBsAg loss at 72 weeks post-treatment were demonstrated when tenofovir disoproxil fumarate (TDF) was combined with pegylated interferon (PEG-IFN) for 48 weeks compared with either monotherapy.
Paper Details　
Original Abstract of the Article :
Hepatitis B surface antigen (HBsAg) loss is the ideal clinical endpoint but is achieved rarely during oral antiviral treatment. A current unmet need in CHB management is achievement of HBsAg loss with a finite course of oral antiviral therapy, thereby allowing discontinuation of treatment. Significa...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244971/

データ提供：米国国立医学図書館（NLM）

A Promising Path for Hepatitis B Treatment

Hepatitis B is a serious liver infection that affects millions of people worldwide. This study focuses on the potential for achieving [hepatitis B surface antigen] (HBsAg) loss, a crucial goal in the treatment of chronic hepatitis B. The researchers investigated the effectiveness of combining [tenofovir disoproxil fumarate] (TDF) with [pegylated interferon] (PEG-IFN) in achieving HBsAg loss.

A Combination Approach for Improved Outcomes

The study found that combining TDF with PEG-IFN for 48 weeks resulted in significantly higher rates of HBsAg loss compared to either monotherapy. These findings suggest that a combination approach may be more effective in achieving this critical endpoint in the treatment of chronic hepatitis B.

Hope for a Cure

The research provides a glimmer of hope for a potential cure for chronic hepatitis B. The findings suggest that a finite course of oral antiviral therapy may be feasible in achieving HBsAg loss, potentially allowing for treatment discontinuation. This would be a significant breakthrough in the management of this challenging disease. Like a camel finding a hidden oasis in the vast desert, this research offers a promising path towards a cure for hepatitis B.

Dr. Camel's Conclusion

This study provides a beacon of hope for millions of people living with chronic hepatitis B. Like a camel navigating the arid desert landscape, researchers are tirelessly searching for ways to effectively treat this challenging disease. The findings suggest that a combination approach may be the key to achieving HBsAg loss, potentially leading to a cure and offering a chance for a healthier future for those affected by hepatitis B.
Date :
  1. Date Completed 2019-04-11
  2. Date Revised 2019-04-11
Further Info :

Pubmed ID

30136045

DOI: Digital Object Identifier

PMC6244971

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.